August 16, 2010
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Keith R. Reinhardt, MD
Sommer Hammoud, MD
Andrea Bowers, MD
David W. Altchek, MD
Answorth A. Allen, MD
Robert G. Marx, MD
Andrew D. Pearle, MD
Anil S. Ranawat, MD
Anne M. Kelly, MD
Beth E. Shubin Stein, MD
Bryan T. Kelly, MD
David M. Dines, MD
Joshua S. Dines, MD
Edward V. Craig, MD. MPH
Howard Anthony Rose, MD
Jo A. Hannafin, MD, PhD
John D. MacGillivray, MD
Michael J. Maynard, MD
Riley J. Williams III, MD
Russell F. Warren, MD
Sabrina M. Strickland, MD
Scott A. Rodeo, MD
Stephen Fealy, MD
Steve J. O’Brien, MD, MBA
Struan H. Coleman, MD, MPH
Thomas L. Wickiewicz, MD
Review of outcomes of revision ACL reconstruction in adolescent patients ages 12-18.
Review of outcomes of revision ACL reconstruction in adolescent patients ages 12-18.
Keith Reinhardt, MD
krr9009@gmail.com
646-678-4402